Author(s)

Habib Cakir, Funda Tor, Hasan Uncu, Ozcan Gur, Mehmet Acipayam, Ozsoyler Ibrahim

Cardiovascular Surgery, Adana Numune Education and Training Hospital, Adana, Turkey.
Cardiovascular Surgery, Katip Celebi University Ataturk Education and Training Hospital, Izmir, Turkey.
Cardiovascular Surgery, Mustafa Kemal University Medicine Faculty, Hatay, Turkey.
Cardiovascular Surgery, Namik Kemal University Medicine Faculty, Tekirdag, Turkey.

Introduction: In this study we explicated early results of patients (the patients in whom levosimendan was used) who underwent coronary artery bypass graft surgery with ejection fraction 35% or less. We compared this group with the patients in whom levo-simendan was not used. Material and Methods: 97 patients who have 35% ejection fraction or less taken to isolated coronary artery bypass surgery between January 2009 and December 2011 in our clinic are chosen for this study retrospectively. We compared the patients in whom levosimendan was used with the patients in whom levosimendan was not used. Levo- simendan (Simdax, Abbott) has been used according to surgeon’s decision in patients. Results: The mean age of group 1 was 62.3 ± 7.6, and the mean age of group 2 was 59.3 ± 10.5 (p > 0.05). It was detected that the average ejection fraction was less in group 1 (p < 0.05). There were no statistically significant difference between the two groups in terms of demand for inotropics, demand for intraaortic balloon pump, revision (because of bleeding), atrial fibrillation, discharging intervals, intensive care unit time, cross clamp and cardiopulmonary bypass time (p > 0.05). It was found that need for blood transfusion were less in group 1 than group 2 (p < 0.05). There were no statistically significant difference between the two groups in terms of mortality (p > 0.05). Conclusion: We consider levosimendan reduces need for blood transfusion in coronary artery bypass graft surgery. This results may change with increasing number of patients so we consider that multicenter larger study is needed.

Levosimendan; Mortality; Coronary Artery Bypass Surgery

Cakir, H. , Tor, F. , Uncu, H. , Gur, O. , Acipayam, M. and Ibrahim, O. (2012) Levosimendan usage in patients with left ventricle dysfunction in coronary artery bypass graft surgery. World Journal of Cardiovascular Diseases, 2, 291-294. doi: 10.4236/wjcd.2012.24045.